Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: Correlation with cognitive benefit

Journal of Neural Transmission

Volumn 109, Issue 7-8, 2002, Pages 1053-1065

  Giacobini, E ^a   Spiegel, R ^b   Enz, A ^b   Veroff, A E ^c   Cutler, N R ^c  

^a Hopital de Geriatrie   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Cerebrospinal fluid; Cholinesterase inhibitor; Cognition; Rivastigmine

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CEREBROSPINAL FLUID ANALYSIS; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BUTYRYLCHOLINESTERASE; CARBAMATES; CHOLINESTERASE INHIBITORS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES;

EID: 0036315026     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020200089     Document Type: Article

References (29)

1. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - A study of molecular forms
2. Acetylcholinesterase in ventricular and cisternal CSF of dogs: Effect of chlorpromazine
3. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
4. Cholinesterases in cerebrospinal fluid. A longitudinal study in Alzheimer disease
5. A new rapid colorimetric determination of acetylcholinesterase activity
6. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
7. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease
8. From molecular structure to Alzheimer therapy
9. Cholinesterase inhibitors: From the calabar bean to Alzheimer therapy
10. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor in patients with Alzheimer's disease
11. Butyrylcholinesterase (BuChE) inhibitors for the treatment of Alzheimer's disease
12. Butyrylcholinesterase in the life cycle of amyloid plaques
13. A comparison of the effects of two inhibitors on brain cholinesterase
14. Physostigmine, tacrine, and metrifonate: The effect of multiple dosage on acetylcholine in rat brain
15. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans
16. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia
17. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain
18. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyse acetylcholine
19. Improved cognition and plasma cholinesterase (ChE) inhibition in AD patients receiving rivastigmine for 1-year: Differential effects across time
20. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment
21. Improved cortical glucose metabolism in Alzheimer's disease (AD) patients treated with rivastigmine for one year
22. Changes in brain cholinesterases in senile dementia of Alzheimer type
23. Molecular forms of cholinesterases in cerebrospinal fluid, blood plasma, and brain tissue of the beagle dog
24. A new assessment tool for neuropsychopharmacologic research: The Computerized Neuropsychological Test Battery
25. Efficacy of Xanomeline in Alzheimer's disease: Cognitive improvement measured using the CNTB
26. Neurological cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability
27. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase
28. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease